Mr. Swapan Kakumanu reports

NETRAMARK PRIVATE PLACEMENT - PRESS RELEASE CLARIFICATION

Netramark Holdings Inc. has provided a clarification to its press release issued Sept. 11, 2023, regarding a non-brokered private placement financing of a minimum of 7.5 million units of the company, for aggregate gross proceeds of not less than $1.5-million, to set out the price of the unit.

Each unit is priced at 20 cents per unit and will consist of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire, subject to adjustment in certain events, one common share in the capital of the company at an exercise price of 35 cents for a period of two years from the closing date of the offering, subject to acceleration in accordance with the terms thereof.

The offering document related to the Offering can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

The closing of the offering is expected to occur on or about Sept. 19, 2023, or such other date or dates as the company may determine.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of artificial intelligence (AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.